Modified Compstatin Peptides for Complement Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for inhibiting the complement cascade, such as compstatin, have limitations in efficacy and specificity, particularly in modulating the activity of C3 and C3b, which are central to the complement activation pathways, and there is a need for further optimization to enhance their activity for treating conditions like age-related macular degeneration and other inflammatory diseases.
Innovation Solution
Development of modified compstatin peptides and peptidomimetics with specific modifications, including N-methyl Gly at position 8, replacement of His with Ala, Val with Trp or its analogs, and acetylation of the N-terminal residue, along with conjugation with polyethylene glycol (PEG) or albumin binding peptides to enhance in vivo retention and activity, resulting in compounds with significantly improved complement-inhibiting activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compstatin peptide is used to inhibit complement activation, then complement inhibition activity is achieved, but the efficacy and specificity are limited
Solution Approach 1:
The patent applies parameter changes by systematically modifying the peptide sequence parameters - replacing specific amino acids (Gly8 with N-methyl Gly, His9 with Ala, Val4 with Trp analogs) and changing structural parameters (cyclic to linear, N-terminal acetylation, C-terminal modifications) to enhance complement inhibition activity while managing structural complexity
Solution Approach 2:
The patent creates composite structures by combining the compstatin peptide framework with additional functional elements such as PEG chains for extended retention and albumin binding domains, resulting in hybrid molecules that achieve both high efficacy and improved pharmacokinetic properties
2Reliability
If peptide modifications are made to enhance activity, then complement inhibition efficacy increases, but molecular complexity increases
Solution Approach 1:
The patent applies local quality by making targeted modifications at specific positions in the peptide sequence rather than uniform changes throughout. Key positions such as 4, 8, 9, and the termini are modified with specific amino acid analogs or chemical groups to locally enhance binding affinity and stability without unnecessarily complicating the entire molecular structure
Solution Approach 2:
The patent segments the peptide modification strategy into distinct modular changes - N-terminal acetylation, specific residue substitutions (Gly8, His9, Val4), C-terminal modifications, and separate PEGylation or albumin binding domain additions - allowing each modification to be optimized independently for its specific function
3Duration of action of stationary object
If PEG or albumin binding peptides are conjugated, then in vivo retention is enhanced, but molecular size increases
Solution Approach 1:
The patent uses PEG chains and albumin binding peptides as intermediary elements that bridge the compstatin core and the physiological environment. These intermediaries extend the peptide's residence time in circulation by reducing renal clearance and enhancing plasma protein binding, respectively, without requiring direct modification of the active binding site
Data Source
AI summary
Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds. The compounds comprise compstatin analogs having a constrained backbone at position 8 (glycine) and, optionally, specific substitutions for threonine at position 13.